Why is Mah Sing eyeing Hong Kong for its healthcare arm listing?

Question

Accepted Answer

Mah Sing Healthcare Aims for Hong Kong Listing Due to Market Advantages

Mah Sing Group Bhd is targeting the Hong Kong Stock Exchange for the potential listing of its healthcare arm, Mah Sing Healthcare Sdn Bhd, within the next five years. This strategic move is driven by the significant advantages the Hong Kong market offers in terms of company capitalization and trading volume, which are considerably higher than those on Bursa Malaysia. The company also sees Hong Kong as a more conducive international hub for fostering business relationships and pursuing mergers and acquisitions.
Greater Market Capitalisation and Trading Volume

The decision to focus on Hong Kong is underpinned by substantial differences in market scale. Companies listed in Hong Kong exhibit a market capitalization approximately 15 times greater than those on Bursa Malaysia. Furthermore, the trading volume in Hong Kong is nearly 20 times that of Bursa Malaysia, indicating a more liquid and active investment environment.
Enhanced Business Connectivity and M&A Opportunities

Beyond financial metrics, Hong Kong's status as an international market facilitates easier establishment of business contacts. This global connectivity is perceived as beneficial for expanding Mah Sing's healthcare operations, particularly in its ambition to engage in more mergers and acquisitions. Such activities are crucial for accelerating growth and consolidating market position within the healthcare sector.
Strategic Diversification and Value Creation

The move to list Mah Sing Healthcare separately from the group is intended to unlock further value and drive creation for stakeholders. This initiative is part of Mah Sing's broader strategy to strengthen and expand its manufacturing division by venturing into the resilient, export-oriented healthcare sector. This diversification aims to complement the group's existing property division, which is subject to market cyclicality and domestic focus.
Operational Milestones in Glove Manufacturing

Mah Sing Healthcare is making tangible progress in its glove manufacturing venture, with the testing and commissioning of its first two production lines completed at its factory in Kapar. Operations are slated to commence next month, with the first shipments of gloves expected within two months. The company plans to have an additional 10 production lines operational by the third quarter of 2021, forming phase one of its glove manufacturing business, with a projected capacity of up to 3.68 billion gloves annually.

Reading history

Hide →

This history is cleared when the page is closed.

Why is Mah Sing eyeing Hong Kong for its healthcare arm listing?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends